title: Soluble CD40 ligand in morbidly obese patients: effect of body mass index on recovery to normal levels after gastric bypass surgery.
abstract: OBJECTIVE
  In recent years, the CD40/CD40L system has been implicated in the pathophysiology of severe chronic inflammatory diseases. Recently, obesity has been described as a low chronic inflammatory disease, so this system could also be involved in the inflammatory process.
  
  
  OBJECTIVE
  To study soluble CD40 ligand (sCD40L) and other factors implicated in coagulation (plasminogen activator inhibitor 1, antithrombin III, and fibrinogen) and inflammation (C-reactive protein) in patients with morbid obesity and different body mass indexes (BMIs) (calculated as weight in kilograms divided by height in meters squared), before and after weight loss induced by bariatric surgery.
  
  
  METHODS
  Plasma samples were obtained before and after a bariatric surgery intervention. Several inflammatory markers were then studied (sCD40L, plasminogen activator inhibitor 1, antithrombin III, and C-reactive protein). The values obtained were compared with a control group of nonobese persons.
  
  
  METHODS
  Thirty-four morbidly obese patients undergoing gastric bypass surgery and 22 normal-weight controls matched for age and sex.
  
  
  METHODS
  A Roux-en-Y gastric bypass was performed in morbidly obese patients.
  
  
  METHODS
  Levels of sCD40L, plasminogen activator inhibitor 1, antithrombin III, fibrinogen, and C-reactive protein 12 months after bariatric surgery.
  
  
  RESULTS
  Obese men showed a tendency for decreased plasma sCD40L levels 1 year after surgery (mean [SEM], 246.5 [70.4] pg/mL before vs 82.2 [23.2] pg/mL after surgery; P < .05), whereas there were not any significant changes in obese women (285.9 [67.5] pg/mL before vs 287.0 [56.9] pg/mL after surgery). Levels of the other markers studied decreased significantly with weight loss in both sexes. However, all other studied markers tend to have higher concentrations in patients with higher BMIs, except for sCD40L, which tended to have lower concentrations in patients with BMIs higher than 55. The decreases with weight loss were lower with higher BMIs for all measurements, except for antithrombin III.
  
  
  CONCLUSIONS
  Increased BMI, but not sex, influences recovery to normal levels for the markers studied, possibly indicating a worse prognosis.
authors: Surgery Unit, Hospital Universitari Arnau de Vilanova, Lleida, Spain.
authors: Juan A
authors: JA
authors: Baena-Fustegueras
authors: Eva
authors: E
authors: Pardina
authors: Eva
authors: E
authors: Balada
authors: Roser
authors: R
authors: Ferrer
authors: Roberto
authors: R
authors: Catalán
authors: Joaquín
authors: J
authors: Rivero
authors: Isidre
authors: I
authors: Casals
authors: Albert
authors: A
authors: Lecube
authors: Jose M
authors: JM
authors: Fort
authors: Víctor
authors: V
authors: Vargas
authors: Julia
authors: J
authors: Peinado-Onsurbe
mesh_terms: D000328:Adult; D015415:Biomarkers / Q000097:blood; D015992:Body Mass Index; D023201:CD40 Ligand / Q000097:blood*; D018450:Disease Progression; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D015390:Gastric Bypass; D006801:Humans; D008297:Male; D008875:Middle Aged; D009767:Obesity, Morbid / Q000097:blood* / Q000601:surgery; D011379:Prognosis; D020127:Recovery of Function; D015431:Weight Loss / Q000502:physiology*
chemical_list: D015415:Biomarkers; D023201:CD40 Ligand